News | September 04, 2012

Japanese Tsunami Brought a Whirlwind of Cardiovascular Risk

Report shows Japanese tsunami brought big increase in cardiovascular hospital calls

Major natural disasters, such as the Japanese tsunami or Hurricane Katrina, are believed to greatly increase cardiovascular events, partly due to the disruption of the pharmaceutical supply chain.

Sept. 3, 2012  — Due to newly released evidence linking the aftermath of Japan’s 2011 earthquake with an increase in the occurrence of cardiovascular (CV) events, new GlobalData analysis has questioned what role disaster might play in the incidence of CV events in areas affected by storms such as Hurricane Isaac.

The great Japanese earthquake and consequent tsunami of March 11, 2011, which hit the northeast coast of Japan with a magnitude of 9.0 on the Richter scale, was one of the largest ocean-trench earthquakes ever recorded in Japan. In addition to claiming the lives of almost 16,000 and destroying nearly 400,000 homes, the disaster resulted in a sharp increase in the number of CV events.

This trend has been reported before, following similar incidences in Japan, China and the United States. According to cardiologist Dr. Hiroaki Shimokawa, however, related studies only reported the short-term occurrence of individual CV events and not the mid-term effects of large-scale earthquakes.

Shimokawa and colleagues from the Tohoku University Graduate School of Medicine at Sendai, Japan, reviewed all 124,152 ambulance transport records in the Miyagi prefecture dating from Feb. 11 to June 30 for each year from 2008 to 2011. Incidence records from before, during and after the disaster were compared, and earthquake aftershocks logged according to a seismic intensity of 1 or greater.

Results showed that the weekly occurrence of five conditions – heart failure (HF), acute coronary syndrome (ACS), stroke, cardiopulmonary arrest (CPA) and pneumonia – were considerably higher in the wake of the disaster than in the previous three years. The occurrence of HF and pneumonia showed a sustained increase for longer than six weeks following the tsunami, whereas those of ACS and CPA showed a rapid increase followed by a sharp decline. It was also found that the incidence of stroke and CPA increased when an aftershock of magnitude 7.0 hit on April 7, 2011.

According to Shimokawa, neither age, sex nor area of residence had a significant impact on the occurrence of CV events during or following the tsunami. The disruption to transport following the tsunami delayed the delivery of medications such as antihypertensive or antithrombotic drugs, which may have contributed to the significant climb in CV events. There was also a jump in the occurrence of ventricular tachyarrhythmias in patients with implantable cardiac defibrillators.

At the European Society of Cardiology (ESC) Congress in Munich, Germany last week, Shimokawa reported that in 2008 the incidence of confirmed cardiovascular disease (CVD) diagnoses in the Miyagi prefecture was 17,000. This increased to 20,000 diagnoses in 2011. Taken all together, Shimokawa believes that the discontinuation of drugs combined with patients’ rising blood pressure and the increased occurrence of tachyarrhythmia and infections contributed to the increased incidence of CV events. 

When it comes to natural disasters such as earthquakes, hurricanes and tornadoes, the resulting disruptions are shown to have a negative impact on the health of the affected population. It is widely accepted through medical research that post-traumatic stress, which is induced by such events, may increase the risk of CV events. As a result, patients who have previously gone undiagnosed with CVD may come to light in the aftermath of such disasters. Accordingly, it is possible that the aftermath of Hurricane Isaac may trigger a surge in the number of CV events and the amount of patients diagnosed with CVD, but when compared to Japan’s 2011 earthquake, the scale is likely to be less substantial.

For a link to the report:

Editor’s note: This expert insight was written by Mayowa Adebiyi, GlobalData's analyst covering cardiovascular and metabolic disorders. GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day.


Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init